Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > nCoat, Inc. Executes Definitive Agreements for $11.85 Million Private Placement

Abstract:
nCoat, Inc. (OTCBB: NCOA) ("nCoat" or the "Company") is pleased to announce the execution of definitive agreements relating to a private placement with institutional and accredited investors for $11.85 million. After the payment of fees and expenses of the private placement, the Company will have received net proceeds of approximately $11 million, which includes $800,000 of outstanding indebtedness converted into this offering.

nCoat, Inc. Executes Definitive Agreements for $11.85 Million Private Placement

WHITSETT, NC | Posted on June 1st, 2007

The securities sold by the Company in the private placement offering consisted of $8,850,000 principal amount of Series A Convertible Notes, $3,000,000 principal amount of Series B Convertible Notes, 22,125,000 Series A Warrants and 7,500,000 Series B Warrants. The Convertible Notes bear interest at a rate of 6% per annum. Of the $11.85 million purchase price of the Notes, $800,000 consisted of the conversion of existing outstanding indebtedness of the Company. The Company has agreed to pay an NASD member firm for its services as placement agent in connection with these offering fees, commissions and reimbursable expenses equal to $810,584.91 and issued 1,293,750 warrants to purchase shares of the Company's common stock. For a more complete description of the private placement offering please see our Current Report on Form 8-K to be filed with the Securities and Exchange Commission on June 1, 2007.

Pursuant to the terms of the transaction documents, the Company may sell an aggregate principal amount of $17.75 million of Notes, with not more than $9,000,000 principal amount being Series A Notes. The Company and the placement agent anticipate additional closings of this offering through June 18, 2007, although there can be no assurance thereof. The Company intends to use the net proceeds from this offering for acquisitions, repayment of indebtedness and for working capital and general corporate purposes.

The Series A Notes are convertible into the Company's common stock at a price of $0.40 per share and the Series A Warrants are exercisable at $1.00 per share, with registration rights covering the resale of the shares of common stock underlying each of the Series A Notes and Series A Warrants. The Series B Notes are convertible into the Company's common stock at a price of $0.40 per share and the Series B Warrants are exercisable at $0.80 per share, the shares of common stock underlying the Series B Notes and Series B Warrants have not been granted registration rights.

In addition to this new infusion of capital, the Company previously received executed agreements from holders of $2,000,000 in convertible debentures, issued by the Company between October 1, 2006 and March 1, 2007, requesting conversion of their convertible debentures, plus accrued interest thereon, into shares of the Company's Common Stock at a rate of $0.50 per share. The Company intends to issue shares to complete this conversion within the next week.

Paul S. Clayson, Chairman and CEO of nCoat, Inc., stated, "This capital raise and conversion of debt to equity significantly strengthens our financial structure and better positions nCoat management to execute our strategic plans, including acquisition of additional companies, internal organic growth and expansion of existing facilities and markets. The investors in this transaction also expand our institutional shareholder base."

The Notes, shares of common stock underlying the Notes, Warrants, and shares of common stock underlying the Warrants have not been registered under the Securities Act of 1933, as amended, and they may not be subsequently offered or sold by investors in the United States until registered or granted an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The Company has agreed to file a registration statement covering the resale of the common stock underlying the Series A Notes and the Series A Warrants.

####

About nCoat, Inc.
nCoat, Inc. is an emerging nanotechnology company focused on the development of new nano-formulated and traditional coatings that make it an international leader in the development and marketing of coatings applied to metal, ceramics, fabric, and other materials. The Company specializes in nanotechnology research, commercialization, licensing, and distribution, and through its subsidiary companies develops and distributes commercially viable proprietary nanotechnology and traditional coatings products. At nCoat, we invite the world to "Innovate with us."

Notice Regarding Forward-Looking Statements

Except for statements of historical fact, the information presented herein may contain forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which nCoat, Inc. has little or no control. Statements in this press release which include words such as "anticipates," "plans," "potential," and similar terms may include forward-looking statements. Factors which could cause the Company's results to differ from the forward-looking statements include a decline or slower-than-anticipated growth in revenue opportunities related to the performance coating industry, and a decline or slower-than-anticipated growth in the demand and use for nano-formulated commercial products and related revenue streams for the Company, as well as listed in the "Risk Factors" sections of the Company's publicly filed reports. The Company expressly disclaims any obligation or intention to update any forward-looking statement.

ON BEHALF OF THE BOARD

nCoat, Inc.

Paul S. Clayson, Chief Executive Officer

For more information, please click here

Contacts:
Investor Relations Contact:
Brad Long
1-866-435-8958

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Materials/Metamaterials/Magnetoresistance

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project